搜索优化
English
全部
Copilot
图片
视频
地图
资讯
购物
更多
航班
旅游
酒店
搜索
笔记本
Top stories
Sports
U.S.
Local
World
Science
Technology
Entertainment
Business
More
Politics
时间不限
过去 1 小时
过去 24 小时
过去 7 天
过去 30 天
按相关度排序
按时间排序
Cure Today
2 小时
You Need Tough Skin With Cancer
Living with lymphoma for 15 years, I developed a concerning rash post-vacation, which led to a leukocytoclastic vasculitis ...
Cure Today
4 小时
Welireg With Cabometyx Elicits Promising First-Line Responses in ccRCC
Researchers have published findings from the phase 2 LITESPARK-003 study of patients with previously untreated advanced clear ...
Cure Today
7 小时
Impact of PV on Lifestyle
A panelist discusses how polycythemia vera (PV) impacts daily life and lifestyle management, including beneficial changes ...
Cure Today
23 小时
Neoadjuvant Tyvyt With Chemo Improve Responses in Resectable, Locally Advanced ESCC
In resectable, locally advanced esophageal squamous cell carcinoma, neoadjuvant Tyvyt plus chemoradiotherapy led to an ...
Cure Today
22 小时
Circulating Tumor DNA May Have Prognostic Value in Kidney Cancer
Dr. Alan Tan spoke with CURE® about what patients with kidney cancer and providers who treat it may be able to learn from ...
Cure Today
1 天
When Cancer Makes You Cry, Cry It Out
One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black ...
Cure Today
1 天
World Cancer Day Shines Light on Therapeutic Advancements in Cancer Care
Dr. John Oertle discussed the significance of World Cancer Day, raising awareness about cancer care advancements and ...
Cure Today
1 天
Weight Gain Measurements May Be Underreported in ALK+ NSCLC Trials
Alecensa weight gain is underreported in ALK+ NSCLC trials, highlighting the need for increased awareness and proactive ...
Cure Today
2 天
Breaking Down Cancer Therapies Approved by the FDA in January 2025
Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...
Cure Today
3 天
ITM-11 Meets Phase 3 Trial Primary End Point of PFS in GEP-NETs
Topline results from the COMPETE trial showed that ITM-11 met the study’s primary end point of PFS in inoperable, progressive ...
Cure Today
2 天
Rybrevant Alone and in Combo With Chemo is Efficacious in HER+ mCRC
Dr. Filippo Pietrantonio discusses OrigAMI-1 trial data which assessed Rybrevant in mutated, wild-type, non-HER2-amplified ...
Cure Today
2 天
Cabometyx Demonstrates PFS Benefit Versus Placebo in GI-NETs
Dr. Jonathan R. Strosberg, discussed results of the CABINET trial evaluating Cabometyx versus placebo in advanced ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈